Needham reiterates DocGo stock rating on SteadyMD strength

DocGo reported Q1 2026 revenue of $75.6 million, beating the $72.43 million consensus, but posted an EPS loss of $0.15 versus expectations for a $0.12 loss. Needham reiterated a Buy rating and $3.00 price target, citing raised FY2026 revenue guidance and expectations that SG&A will decline sequentially as cost cuts flow through. The outlook is mixed near term, but management's visibility into second-half profitability and stronger top-line drivers from SteadyMD and the payor business is constructive.

Analysis

The key signal is not the quarter itself but the shape of the next two quarters: this is a classic “earnings lag vs. narrative inflection” setup where the market is still pricing current-period margin friction while the business mix is improving underneath. If the cost-cutting pass-through is real, the P&L should mechanically improve faster than consensus once SG&A resets, which matters more than the one-off miss in a quarter where revenue already proved the topline engine is intact. In that framework, the biggest beneficiary is not just the stock, but any capital allocation decision that gets funded by a higher-confidence second-half margin ramp.

The second-order effect is competitive. A company that can keep pulling through higher-value managed services while stabilizing margins can pressure smaller healthcare services peers that lack scale or have more variable labor-cost exposure; those competitors may have to defend share with pricing or spend, which can delay their own margin normalization. The counterpoint is execution risk: if SG&A declines do not show up sequentially by the next 1-2 quarters, the market will reclassify this as a structurally low-quality revenue model rather than a temporary timing issue, and the downside can be abrupt because the stock already trades like a distressed optionality name.

The contrarian view is that consensus may be underestimating how much of the upside is already embedded in the “profitability by year-end” story. A sub-$1 stock with a large headline target can attract reflexive upside, but if the balance sheet or working-capital profile is still tight, equity value can remain hostage to even small misses in cash burn or receivables collection. The most important catalyst window is the next earnings print plus any intra-quarter commentary on hiring, utilization, and client concentration; absent hard evidence, the market may keep demanding proof before rerating.

Key Decisions for Investors

• Long DCGO as a 1-2 quarter tactical trade, sized small: asymmetric if SG&A normalizes, but high volatility means the position should be treated as event-driven rather than core exposure.
• Buy near-dated call spreads in DCGO ahead of the next earnings/catalyst window: targets the rerating if the market starts discounting second-half margin inflection, with defined downside versus common stock.
• Pair trade: long DCGO / short a higher-multiple healthcare services peer with weaker margin visibility over the next 2-3 months; the relative trade should work if investors reward operating leverage rather than absolute growth.
• Set a hard stop if management does not show sequential SG&A improvement on the next update; failure there would invalidate the timing thesis and likely compress the equity further.
• If the stock rallies on the analyst note alone, fade part of the move rather than chase: the risk/reward improves after the market proves it believes in the second-half margin bridge, not before.